Perspective
Feb. 13, 2013
'Obviousness' test for chemical compounds survives
The U.S. Supreme Court has declined to hear a Federal Circuit case re-affirming the lead compound analysis for determining the obviousness of a new chemical compound. By Pauline Farmer-Koppenol
In Otsuka Pharmaceutical Co., Ltd. v . Sandoz, Inc., et al., 678 F.3d 1280 (2012), the Federal Circuit Court of Appeals has re-affirmed the lead compound analysis for determining the obviousness of a new chemical compound. The defendants in the case had argued that lead compound analysis was too rigid in light of KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727 (2007), and filed a petition for certiorari with...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In